Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Deucravacitinib and Adalimumab for the Treatment of Relapsed Takayasu's Arteritis: The TYK-TAK Trial

NCT07013838 is registered in ClinicalTrials.gov with Chinese SLE Treatment And Research Group as lead sponsor.

NCT NCT07013838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07013838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Deucravacitinib and Adalimumab for the Treatment of Relapsed Takayasu's Arteritis: The TYK-TAK Trial
Lead sponsor
Chinese SLE Treatment And Research Group
Phase
Phase 4
Overall status
Not yet recruiting
Start date
June 15, 2025
Completion date
March 31, 2028
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

takayasu arteritis (tak)